Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorHernández Jiménez, Macarena
dc.contributor.authorAbad-Santos, Francisco
dc.contributor.authorCotgreave, Ian
dc.contributor.authorGallego, Jaime
dc.contributor.authorJilma, Bernd
dc.contributor.authorFlores, Alan
dc.contributor.authorMolina Cateriano, Carlos
dc.contributor.authorRibó Jacobi, Marc
dc.date.accessioned2023-03-24T11:38:28Z
dc.date.available2023-03-24T11:38:28Z
dc.date.issued2023-02-24
dc.identifier.citationHernández-Jiménez M, Abad-Santos F, Cotgreave I, Gallego J, Jilma B, Flores A, et al. APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke. Front Neurol. 2023 Feb 24;14:1127585.
dc.identifier.issn1664-2295
dc.identifier.urihttps://hdl.handle.net/11351/9242
dc.descriptionInflamació; Neuroprotecció; Ictus
dc.description.sponsorshipThe study is supported by grants from the Spanish Ministry of Science, Innovation and Universities (RTC-2017-6651-1 and RTC2019-006795-1). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Neurology;14
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMalalties cerebrovasculars - Tractament
dc.subjectAssaigs clínics
dc.subject.meshStroke
dc.subject.mesh/drug therapy
dc.subject.meshDouble-Blind Method
dc.titleAPRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fneur.2023.1127585
dc.subject.decsaccidente cerebrovascular
dc.subject.decs/farmacoterapia
dc.subject.decsmétodo doble ciego
dc.relation.publishversionhttps://doi.org/10.3389/fneur.2023.1127585
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Hernández-Jiménez M] AptaTargets S.L., Madrid, Spain. [Abad-Santos F] Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Cotgreave I] Division of Bioeconomy and Health, Department of Chemical and Pharmaceutical Safety, Research Institutes of Sweden, Södertälje, Sweden. [Gallego J] Neurological Center of Navarra, Navarra, Spain. [Jilma B] Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. [Flores A] Stroke Unit, Hospital Joan XXIII, Tarragona, Spain. [Molina CA] Unitat d’Ictus, Servei de Neurologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Ribo M] AptaTargets S.L., Madrid, Spain. Unitat d’Ictus, Servei de Neurologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid36908619
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple